Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CDKN2A mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

CDKN2A mutation	Triple Negative Breast Cancer	CDKN2A mutation	Triple Negative Breast Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
CDKN2A mutation	Breast Cancer	CDKN2A mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
CDKN2A mutation	Gallbladder Cancer	CDKN2A mutation	Gallbladder Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
CDKN2A mutation	Clear Cell Renal Cell Carcinoma	CDKN2A mutation	Clear Cell Renal Cell Carcinoma	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
CDKN2A mutation	Pancreatic Cancer	CDKN2A mutation	Pancreatic Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
CDKN2A mutation	Solid Tumor	CDKN2A mutation	Solid Tumor	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2A mutation	Melanoma	CDKN2A mutation	Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2A mutation	Urothelial Cancer	CDKN2A mutation	Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2A mutation	Biliary Tract Cancer	CDKN2A mutation	Biliary Tract Cancer	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3
CDKN2A mutation	Non Small Cell Lung Cancer	CDKN2A mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3